Between pharmaceutical patents and European patients: is a compromise still possible?-Reference-Cited by-同舟云学术

Between pharmaceutical patents and European patients: is a compromise still possible?

Published:2017-07-10 Issue:10 Volume:27 Page:1073-1076
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Garattini Livio¹,Padula Anna¹

Affiliation:

1. IRCCS Institute for Pharmacological Research “Mario Negri”, Ranica, Italy

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2017.1350648

Reference28 articles.

1. World Intellectual Property Organization, WIPO. What is intellectual property? WIPO Publication No. 450(E); Geneva, 2004. ISBN 978-92-805-1555-0. 25.

2. The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals

4. After Thalidomide – Do We Have the Right Balance Between Public Health and Intellectual Property

5. Patent nonsense: Evidence tells of an industry out of social control

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary challenges in the European pharmaceutical industry: a systematic literature review;Measuring Business Excellence;2022-11-08

2. Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid?;Applied Health Economics and Health Policy;2021-11-29

3. Pharmaceutical patenting in the European Union: reform or riddance;Internal and Emergency Medicine;2021-11-15

4. Pricing vaccines and drugs in Europe: worth differentiating?;The European Journal of Health Economics;2020-06-23

5. Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?;Journal of the Royal Society of Medicine;2019-12-20